For more information contact:
John L. Tonkinson, Ph.D., Chief Business Development Officer
Main: +1-760-804-3886 | Mobile: +1-860-977-4012
FOR IMMEDIATE RELEASE
September 25, 2018
CARLSBAD, Calif. and CAMBRIDGE, Mass.—DCN Dx, a developer and manufacturer of rapid point-of-care diagnostic tests, and E25Bio, an MIT-spinoff diagnostics company from the Gehrke Lab at IMES, have announced a partnership for the design, development and manufacture of an innovative new infectious disease testing technology.
Developed and commercialize by E25Bio, this new technology is a rapid, low-cost, highly-specific and sensitive method for onsite detection and global epidemiological analysis of dengue, Chikungunya and Zika viruses in one device.
DCN provides complete design, development and manufacturing services for rapid diagnostic assays and associated disposable devices at its ISO 9001:2015 and EN 13485:2016 certified facility in Carlsbad, CA. DCN will develop the technology into a highly-functional and accessible multiplexed product that can be deployed for in-field use around the world. E25Bio’s mission is to prevent severe downstream health outcomes through affordable and early detection. The organization is currently funded by The Engine.
“Dengue, Chikungunya and Zika illnesses have rapidly expanded across the globe in recent years, causing large-scale outbreaks worldwide,” commented E25Bio’s CEO & Founder, Irene Bosch, PhD. “With 3.8 billion people in endemic areas and 128 countries affected by mosquito-borne viruses, swift diagnostics are crucial for patient treatment and the management of epidemics. The low cost of E25Bio’s RDT technology makes the point-of-care test more accessible to communities worldwide.”
“These diseases are major threats to health and safety all around the world,” said DCN Dx President Brendan O’Farrell. “We’re pleased to partner with E25Bio to leverage DCN’s expertise and talent to develop this groundbreaking, life-saving product for worldwide use.”
As Dr. Bosch explained, “Through affordable and early detection, our mission is to prevent severe downstream health outcomes. Mobile and rapid diagnostics can facilitate real-time reporting, which in turn can provide large datasets to guide informed responses for the control of disease spread.”
Since its founding more than 12 years ago, DCN Dx has been committed to furthering the rapid diagnostic test market through the continued evolution of technologies and applications related to lateral flow assays. For more information about DCN Dx, visit dcndx.com.
E25Bio is an enterprise for innovation in the field of emerging disease diagnostics founded by Dr. Irene Bosch and MIT Professor Lee Gehrke. For more information, visit E25bio.com.